Genflow Biosciences announced that its SLAB clinical trial testing the SIRT6 gene therapy in aged dogs met its primary endpoint, demonstrating a clear improvement in biological age compared to controls. The trial involved 24 dogs over ten years old, using different doses and delivery methods. This milestone supports further discussions with potential animal health partners and will be detailed at the upcoming Animal Longevity Summit. Genflow also continues developing therapies for liver and eye diseases.
Canada has enacted retaliatory tariffs ranging from 15% to 50% on $27.6 billion worth of U.S. products, including steel, aluminum, dairy, and electronics, following the collapse of trade negotiations with the U.S. These tariffs aim to counter U.S. le...
Power Metallic Mines Inc. has released an updated Mineral Resource Estimate for its Nisk Project in Quebec, including the first resource for the high-grade Lion Zone, containing approximately 406 million pounds of copper equivalent (CuEq) with over 8...
Ethereum mid-tier holders sold 307K ETH last week, outpacing the 82K ETH bought by large holders, signaling retail profit-taking near $2,265 acquisition costs. ETF inflows fell sharply to $218.4M from $824M, reflecting weakening institutional demand....
Dunelm Group PLC announced a three-year strategy to accelerate sales growth to mid-to-high single digits by cutting £100 million in unproductive costs and investing in store and digital expansion. The plan includes opening up to ten new stores annual...
Computacenter PLC has raised its full-year profit forecast for 2026 following a record first half, driven by strong demand for AI and digital infrastructure in North America and the UK. The company now expects adjusted profit before tax to be at leas...
